Evaluation of Clinical Significance and Feasibility of CT Guided Biopsy of Double Site Lesions：A Preliminary Lung Centered Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04960631

Enrollment

134

Registered

2021-07-14

Start date

2018-03-01

Completion date

2018-05-31

Last updated

2021-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma of the Lungs

Brief summary

This study aims to explore the clinical significance and feasibility of double site biopsy by analyzing the pathological characteristics and the incidence of main complications of CT guided puncture biopsy of lung and other parts coexisting lesions.

Detailed description

CT guided biopsy is minimally invasive, accurate and low cost. It is often used as an important diagnostic method when the clinical suspect of malignant disease or the treatment effect of the disease is not good. In patients with suspected malignant lung disease, metastasis of other parts of lung, pulmonary door, mediastinum, bone, and distant soft tissue may be combined at the same time. It is the key link of clinical work to evaluate the nature of these coexisting lesions accurately and choose appropriate treatment methods. At present, there is little clinical study on lung centered double site biopsy. This study aims to explore the clinical significance and feasibility of double site biopsy by analyzing the pathological characteristics and the incidence of main complications of CT guided puncture biopsy of lung and other parts coexisting lesions.

Interventions

DIAGNOSTIC_TESTDouble site CT guided needle biopsy

Double site CT guided needle biopsy

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with suspected malignancy * underwent dual site CT guided biopsy in the Third Hospital of Peking University

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
for the combination of two site biopsies	up to 2weeks	The incidence of 4 kinds of combined pathological results in different lesion location groups was analyzed.
for the combination of two site biopsy approaches 1	up to 2weeks	The incidence of pneumothorax on the surgical side after unilateral lung biopsy
for the combination of two site biopsy approaches 2	up to 2weeks	the incidence of pneumothorax on the surgical side after bilateral lung biopsy
for the combination of two site biopsy approaches 3	up to 2weeks	the incidence of intra tissue hemorrhage after biopsy were statistically analyzed.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026